

C. P. 3950 Lévis (Québec) G6V 8C6 <u>desjardinslifeinsurance.com/planmember</u> 1-844-410-6485

PRIOR AUTHORIZATION REQUEST ZOMETA (ZOLEDRONIC ACID)

PLEASE READ THE INSTRUCTIONS ON THE BACK OF THIS FORM.

	PATIENT IDENTIFICATI	ON – To be completed by the me	mber.							
	Patient's last and first name	e		Relationshi	p with member			late of birth		
				☐ Membei	Spouse	Dependent chil	d YYYYY	MM DD		
	Member's last and first nar	me			Contract No.		Certificate No.			
	No shoot out									
	No., street, apt.		City				Province	Postal code		
	Telephone Nos – Home:	Office request includes confidential infor			nsion:	Email:				
	_ '	•	* •	,	By fax:					
	By mail (The response to your request will be sent to the address indicated in this section.) By fax: Coordination of benefits: If the patient has coverage under a private insurance plan or is enrolled in a provincial drug insurance plan, please submit the request to this plan first. Then send us a copy of the decision notice and this form filled out by the physician, so we can analyze the request.									
		Does the patient have drug coverage under a private insurance plan?								
		Yes – Please provide a copy	of the notice of approv	al or refusal.	$ ightarrow$ \Box Copy	attached to this for	m.			
	PRIVATE PLAN	Specify: Name of the insurer:			Contract No	.:	_ Certificate No	0.:		
		□No								
		Has a request for reimbursem	ent been submitted und	der your prov	incial plan?					
	PROVINCIAL PLAN	☐ Yes — Please provide a copy of the notice of approval or refusal. → ☐ Copy attached to this form.								
		No – Please explain:	■ No – Please explain:							
	PATIENT SUPPORT	Is the patient enrolled in a pat	ient support program?	Yes	No					
	PROGRAM	If so – Program name:								
		Contact person:			Telephor			Extension:		
1		JTHORIZATION FOR THE COI provided on the claim form is a								
	the information deemed ne and insurance companies; (when necessary use the pe	urposes of managing my file and secessary to manage my file. The no (b) communicate to the said person resonal information it may have about the said may have about the control of the co	on-exhaustive list of sou ns or organizations only out me in existing files th	rces from whi the personal nat are now cl	ich information ma information about osed. This authori	ay be collected includ t me that is deemed r zation is also valid for	hes healthcare processary for the the collection,	professionals or facilities, ie purposes of my file; (c)		
	Signature of member:					Date:				
	Last name and first name of	of parent/legal guardian (if applic	able):							
	Signature of patient or par	ent/legal guardian (if applicable)	:			Date:				
2		MUNICATION OF PERSONA								
		aim more efficiently, do you auth f the reasons for the decision on y			n the patient sup	port program and th	e attending ph	lysician or the attending		
	Yes No									
	ignature of member: Date:									
	Last name and first name of	of parent/legal guardian (if applic	able):							
	Signature of patient or par	or parent/legal guardian (if applicable): Date:								
	ATTENDING PHYSICIAN SECTION – To be completed by the attending physician.									
	Physician's last and first name (PLEASE PRINT)		Lic	ense No.	Specialty					
	No., street, suite City						Province	Postal code		
							Trovince			
	Telephone No.:			Fax No.:						
•	Signature of physician:					Date:				
	Drug name		Formulation S	trength	Dosage		Scheduled du	ration of treatment		
	Where is the drug administ	ered? Home Phy	sician's office P	rivate clinic	☐ Hospital – II	npatient Hosp	oital – Outpatie	nt		
		Other (please spe	ecify):							
_										

ATTENDING PHYSICIAN SECTION – Continued

- Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member.
- In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context.

Bone events in a person with a solid tumor		
Bone events in a person with multiple myeloma		
Tumor-induced hypercalcemia		
Other therapeutic indication(s) - Please specify:		
formation about hypercalcemia or bone events in	a person with a solid tumor or multiple myeloma	
pes the patient have at least one bone metastasis?	☐ Yes ☐ No	
RIOR MEDICATION OR TREATMENT as the patient ever used medication or received treatm	nent for this medical condition?	
not, please explain:		
so, please list any medication already used or any trea	tment already received for this medical condition:	
MEDICATION OR TREATMENT NAME	ОИТСОМЕ	TREATMENT PERIOD
Name:	Inefficiency Intolerance Contraindication	From:
Dose:	Specify:	To:
Name:	Inefficiency Intolerance Contraindication	From:
Dose:	Specify:	To:
Name:	Inefficiency Intolerance Contraindication	From:
Dose:	Specify:	To:
	Inefficiency Intolerance Contraindication	From:
Name:		
Name: Dose:	Specify:	To:
	Specify:	I

- 1. Complete sections A and B.
- 2. Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information.
- 3. To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.

4. Send form: by fax: Desjardins Insurance

Group Insurance, Health Claims,

by mail: Desjardins Insurance Group Insurance, Health Claims

C. P. 3950, Lévis (Québec) G6V 8C6

418-838-2134 or 1-877-838-2134 (toll-free)

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.